To validate these findings further, we performed a similar analysis on a validation set of tumor samples from 19 independent NSCLC patients with EGFR-WT (n = 9) or EGFR-MT (n = 10) (Supplementary Data 5a). This evidence concerns the gene EGFR and non-small cell lung carcinoma.